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Cancer remains a major public health problem in many countries. It was found to contain a subset of cancer stem cells (CSCs) that
arecapableofproliferationandself-renewal,anddiﬀerentiationintovarioustypesofcancercells.CSCsoftendisplaycharacteristics
of chemotherapy resistance and radiotherapy resistance. Numerous putative biomarkers of CSCs are currently identiﬁed including
CD133, CD44, CD24, ALDH (aldehyde dehydrogenase), and ABCG2. Interestingly, no single marker is exclusively expressed by
CSCs. Thus, the various combinations of diﬀerent biomarkers will be possible to identify CSCs, and considerable work is being
done to recognize new ones. In order to demonstrate the mechanisms of resistance and response to therapy and predict the
outcome as well as prognosis, the ways to track and identify CSCs will be extremely important. The technologies of molecular
imaging will reveal mechanisms of cancer progression and provide visual targets for novel therapeutics. Limited studies were
investigated on the detection of various types of CSCs by molecular imaging. Although the tracking of circulating CSCs is still
hampered by technological challenges, personalized diagnosis and therapies of cancers are expected to be established based on
increased understanding of molecular imaging of cancer stem-like cells biomarkers.
1.Introduction
The global burden of cancer is increasing, and cancer is a
major public health problem in many parts of the world,
including China. Based on the American Cancer Society
cancer statistics, a total of 1,596,670 new cancer cases and
571,950 deaths from cancer, corresponding to more than
1500 deaths per day, are projected to occur in the United
States in 2011 [1]. Among men cancers of the prostate, lung
and bronchus, and colorectum will account for approxi-
mately 52% of all newly diagnosed cancers. Breast, lung and
bronchus, and colorectum will be the three most commonly
diagnosed types of cancers among women this year. Cancers
of the lung and bronchus, prostate, and colorectum in men,
andcancersofthelungandbronchus,breast,andcolorectum
in women continue to be most common causes of cancer
death. These four cancers account for almost half of the total
cancer deaths among men and women [1].
Cancer mortality remains high, despite the recent
advances made in cancer treatment and diagnosis. One
possible cause for therapeutic failure is that many malignant
tumors contain a subset of tumor-initiating cells termed
cancer stem cells (CSCs) when multipotency and self-
renewal have been demonstrated. The CSC model provides
an attractive concept that help to explain why cancer cells
resistant to chemo- and radiotherapies. There has been
acceptance of the idea that the remaining tumor cells after
anticancer therapy have a distinct molecular phenotype that
confers resistance to the therapies [2, 3]. Identiﬁcation and
puriﬁcation of the CSC population from clinical samples
and cell lines have been proven successfully based on the
expression of a particular cell-surface marker, as well as by
functional assays. The identiﬁcation of CSC has undergone
rapid development in recent years.
Side population (SP) technology has been widely used
to identify the cancer stem-like cells by detection of the2 Journal of Biomedicine and Biotechnology
ability to eﬄux Hoechst 33342 dye through an adenosine-
triphosphate-(ATP-) binding cassette (ABC) membrane
transporter. In many tumors, SP cells are reported as en-
riched cells with tumorigenesis and are responsible for
chemoresistance and tumor recurrence [4–6]. The current
methodsforisolationofputativeCSCsdependoncellsurface
biomarkers and enzymatic activity detected by ﬂuorescence-
activated cell sorter (FACS). Clariﬁed understanding and
eradication of CSCs, in turn, may improve the outcome of
some cancer therapy [3, 7]. One of the promising strategies
is to track the CSCs and then target them for eﬃcient
treatments. Techniques required for real-time imaging and
studies of tumor cells in viable fresh tissue or living animals
are urgently needed.
Molecular imaging is a new and noninvasive strategy
which can provide molecular and physiological information
regarding cancer using various molecular-targeted imaging
probes speciﬁc for cell surface biomarkers that are unique
to cancer. It aims to visualize and quantify biological, phys-
iological, and pathological processes on cellular and molec-
ular levels. This has advantages over traditional methods,
as they permit real-time tracking in vivo. Based on the
biological characteristics of cancer stem cells, molecular
imaging will provide a novel role for the visualization
of cancer cells. Intravital imaging of CSCs could be of
great importance for determining prognosis, as well as
monitoring therapeutic eﬃcacy and inﬂuencing therapeu-
tic protocols. Cancer biomarker-based molecular imaging
has become an essential element for cancer diagnosis. In
most cases, the accuracy of predicting cancers depends on
the speciﬁcity and signal sensitivity of molecular probes
targeting genes or proteins involved in cancer growth and
progression. In this paper, we will brieﬂy discuss and
summarize cancer stem biomarkers and the applications of
the molecular imaging in tumor stem-like cells or tumor
cells.
2.TypesofCancerStemCellsand
Its Biomarkers
CSCs have been deﬁned as a subset of cancer cells with exclu-
sive ability of self-renewal and to cause the heterogeneous
lineages of cancer cells that comprise the tumor. Numerous
putative markers are currently under investigation, and
much work is being done to identify and characterize new
marker. The experimental methods to identify CSCs have
been developed so far as follows: (a) clonogenic assay;
(b) sphere-forming assays; (c) assays to investigate the
diﬀerentiation potency of isolated cells into the various
diﬀerentiated cells. In addition to these analyses based on
in vitro properties of CSCs, the existence of CSCs has
been demonstrated by tumor initiation assays, in which
the primary human tumor cells were transplanted into
NOD/SCID mice [8–10]( Figure 1). Cell surface markers
and enzymatic activity detected by FACS have been widely
used for the prospective isolation of putative CSCs. Here,
the biomarkers to identify CSCs in diﬀerent types of tumor
models are investigated.
2.1. Hematopoietic System: Acute Myelogenous Leukemia
(AML). In 1994, Lapidot et al. showed that leukemia can
be initiated in mice using a single tumorgenic cell. It
implied that a single or a few malignant cells can produce
tumors [11]. These leukaemia-initiating cells were found to
be CD34+ CD38− on the basis of the cell-surface-marker
expression. Subsequently, Bonnet et al. also demonstrated
that the cell capable of initiating human AML in nonobese
diabetic mice with severe combined immunodeﬁciency
disease (NOD/SCID mice), termed the SCID leukemia-
initiating cell, was exclusively CD34+ CD38− [12]. After
the identiﬁcation of rare CSCs in leukemia, numbers of
molecular markers for detecting CSCs in solid tumors have
also been identiﬁed. The models that have been devised to
describe the CSCs are as follows.
2.2. Solid Tumors: Brain/Breast/Lung/Colorectal/Prostate/
Pancreas/Liver
2.2.1. Brain. Brain tumors are the leading cause of cancer
mortality in children and remain incurable despite advances
in surgery and adjuvant therapies [1]. Singh et al. reported
that only the CD133+ brain tumor fraction contains cells
that were capable of tumor-initiation in NOD-SCID mouse
brains [13]. They used a xenograft assay that identiﬁed
human brain tumor initiating cells that initiate tumors in
vivo. In their studies, injection of 105 CD133− cells did not
form a tumor, whereas only 100 CD133+ cells produced the
patient’s original tumor. This identiﬁcation of an in vivo
tumor-initiating cell from human brain tumors provided
a powerful tool to investigate the tumorigenic process in
the central nervous system. Interestingly, Chiao et al. sug-
gested that CD133+ glioblastoma stem-like cells (GSCs) and
CD133− GSCs shared similar eﬃcacy in tumor formation
but showed distinct intratumor vasculature [14]. Compared
with CD133− GSC, a highly vascularized anaplastic tumor
was found in CD133+ GSC-derived tumor xenografts. Both
in vitro and in vivo subsets of CD133+ GSC but not
CD133− GSC were capable of vascular smooth muscle-like
cell diﬀerentiation. The detection of endothelium-associated
CD31 gene and diﬀerentiation of vascular-like cells suggest
that GSCs may contribute to form vessel-like structures and
provide a blood supply for glioblastoma cells.
Additionally, Tabuse et al. found high expression of the
HOXD9 gene transcript in glioma cell lines and human
glioma tissues [15]. They suggested that HOXD9 would
be a novel marker of GCSCs and cell proliferation and/or
survival factor in gliomas and glioma cancer stem-like cells,
and a potential therapeutic target (HOX genes encode a
family of homeodomain-containing transcription factors
involved in the determination of cell fate and identity during
embryonic development. They also behave as oncogenes in
some malignancies).
2.2.2. Breast. Breast cancer is the most frequently diagnosed
cancer and the leading cause of cancer death among females,
accounting for 23% of the total cancer cases and 14% of the
cancer deaths, based on the GLOBOCAN 2008 estimates [1,Journal of Biomedicine and Biotechnology 3
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Figure 1: Three phenotypes of CSCs: self-renew, multipotentiality, and tumor-initiating capacity. Self-renewal: single-cell culture sphere-
forming assay. Diﬀerentiation: ﬂow cytometric analysis of diﬀerentiation markers and loss of stem cell markers. Tumor-initiating properties
were investigated by injection of CSCs in NOD/SCID mice. The most crucial standard for a CSC is its ability to reinitiate a serially
transplantable tumor that recapitulates the original heterogeneity and tumor histology. Using this standard, many so-called CSCs reported
so far are based on correlative studied rather than being true CSCs.
16]. In the United States, breast cancer is expected to account
for 30% (230, 480) of all new cancer cases among women
in 2011 [1] .T h r o u g ha n a l y s i so fc e l ls u r f a c em a r k e r sa n d
xenotransplant models, a subpopulation of putative human
breast cancer stem cells that is CD24−/CD44+ and bears
high aldehyde dehydrogenase isoform 1(ALDH1) activity
has been isolated in clinical samples of breast cancer tissues
[3]. These cells are regarded as having the most prominent
tumor-initiating activity. Cells with aldehyde dehydrogenase
(ALDH) activity isolated from normal human breast have
phenotypic and functional characteristics of mammary stem
cells. Analyzing the expression of ALDH1 in hundreds of
human breast carcinomas from two independent tumor sets
indicated poor clinical outcome [17]. These ﬁndings provide
support for the “cancer stem cell hypothesis” and further
indicated that ALDH1 was a marker of stem/progenitor cells
of the normal human breast and breast carcinomas. The
ALDH1-positive cell population had a small overlap with the
previously described cancer stem cell, CD44+/CD24−/lin-
phenotype [18].
The overlap represented approximately 1% or less of the
total cancer cell population, which bears both phenotypes
appeared to be highly enriched in tumorigenic capability.
I tw a sf o u n dt h a ta sf e wa s2 0c e l l sw e r ea b l et og e n e r a t e
tumors. Since ALDH is also expressed in hematopoietic
and neuronal stem cells, this marker may prove useful for
the detection and isolation of cancer stem cells in other
malignancies, thus facilitating the application of cancer stem
cell biology to clinical practice. In breast CSCs, it was also
showed that the activity of TAZ, a transducer of the Hippo
pathway, is required to sustain self-renewal and tumor-
initiation capacities. TAZ protein levels and activity, which is
promoted by the epithelial-mesenchymal transition (EMT),
are elevated in prospective CSCs and in poorly diﬀerentiated
human tumors, which have prognostic value [19]. The
Hippo transducer TAZ confers cancer stem cell-related traits
on breast cancer cells.
2.2.3. Lung. Lung cancer is the third most commonly
diagnosed type and third most common cause of cancer
death both in male and female [1]. Similar to the limited
understanding of lung stem cell biology, the identity of the
cell of origin in lung tumorigenesis is also largely unknown.
Lung cancer contains a rare population of CD133+ cancer
stem-like cells able to self-renew and generates an unlimited
progeny of nontumorigenic cells. Molecular and functional
characterization of such a tumorigenic population may
provide valuable information to be exploited in clinic [20].
It was found that human lung CSCs also express ABCG2, c-
kit receptors, embryonic markers (SSEA-3, TRA-1-81, Oct-
4, and nuclear β-catenin), and low levels of the cytokeratins
8/18 (CK8/18) [21, 22].4 Journal of Biomedicine and Biotechnology
2.2.4. Colorectal Cancer. Colorectal cancer is the third most
commonly diagnosed cancer in males and the second in
females [1]. Colorectal cancer incidence rates are rapidly
increasing in several areas historically at low risk, of which
possible reasons are a combination of factors including
changes in dietary patterns, obesity, and an increased
prevalence of smoking.
The existence of human colon cancer tumor-initiating
cells was demonstrated by O’Brien et al. [10]. They used
the renal capsule transplantation in immunodeﬁcient NOD/
SCID mice to identify a human colon cancer-initiating cell
(CC-IC), which was CD133+. However, the CD133− cells
that comprised the majority of the tumor were unable
to initiate tumour growth. They calculated by limiting
dilution analysis that there was one CC-IC in 5.7 × 104
unfractionated tumor cells, whereas there was one CC-IC in
262 CD133+ cells, representing >200-fold enrichment. CC-
ICs within the CD133+ population were able to maintain
t h e m s e l v e sa sw e l la sd i ﬀerentiate and reestablish tumor
heterogeneity upon serial transplantation. The identiﬁcation
of colon cancer stem cells and the existence of tumorigenic
and nontumorigenic cells within colon cancers suggested
that they must target the cancer stem cells for therapeutic
strategies to be eﬀective.
Simultaneously, tumorigenic cells in colon cancer were
included in the high-density CD133+ population, which
accounted for about 2.5% of the tumor cells [9]. The
original tumor in NOD/SCID mice can be reproduced by
injection of colon cancer CD133+ cells. Puriﬁed CD133
andcarcinoembryonicantigen-positive(CEA+)c oloncanc er
cells were unable to transfer the tumor into immunocom-
promised mice, and the tumorigenic population in colon
cancer is restricted to CD133+ cells. Importantly, CC-ICs
need to remain undiﬀerentiated to maintain tumorigenic
potential. During the in vivo passages, the tumors were
serially transplanted for several generations, and CD133+
cells did not lose their tumorigenic potential. Instead,
in each of the tumors they observed progressively faster
tumour growth without signiﬁcant phenotypic alterations.
Therefore,thesmallnumberofundiﬀerentiatedtumorigenic
CD133+ cells should be the target of future therapies.
Using multiple genetic markers, researchers also had
evaluated the clinical signiﬁcance of circulating tumor cells
as a prognostic factor for overall survival (OS) and disease-
free survival (DFS) in the peripheral blood (PB) of patients
with colorectal cancer Dukes’ stages B and C who had
undergone curative surgery. OS and DFS of patients who
were positive for CEA/CK/CD133mRNA were signiﬁcantly
worse than those of patients who were negative for these
markers. Detection of CEA/CK/CD133 mRNA in PB is a
useful tool for determining which patients are at high risk
for recurrence and poor prognosis [23]. Moreover, in human
colorectal cancer, CSCs are also deﬁned using CD166, CD44,
and CD24 cell-surface markers [24, 25].
The CSC theory suggests that the actual tumorigenic
capacity of individual cancer cells may be inﬂuenced by
homeostatic signals derived from their microenvironment. It
was observed that high Wnt activity functionally designates
the colon CSC population [26]. Nevertheless, the current
datalendstrongsupporttotheinﬂuenceofthenicheonCSC
maintenance.
2.2.5. Prostate. Prostate cancer will account for 29% (240,
890) and be most commonly diagnosed cancer in men in
United States according to the American Cancer Society in
2011 [1]. There continues to be a need for new diagnostic
markers and potential new therapeutic targets in prostate
cancer. Studies suggested that high ALDH activity and
coexpression of CD44 (ALDHhi CD44+) cells exhibited
a higher proliferative, clonogenic, and metastatic capacity
in vitro and demonstrated higher tumorigenicity capacity
in vivo in prostate cancer cell line. However, low ALDH
activity and CD44-negative (ALDHlo CD44−) cells were able
to develop tumors, albeit with longer latency periods. In
their study, ALDH activity and CD44 did not appear to
identify prostate cancer stem cells; however, they did reveal
increased tumorigenic and metastatic potential, indicating
their potential importance for further exploration [28].
Rajasekhar et al. identiﬁed a minor subset of stem-like
human prostate tumour-initiating cells (TICs) that do not
express prostate cancer markers, such as androgen receptor
or prostate-speciﬁc antigen [29]. The cells represent an
undiﬀerentiated subtype of basal cells and can be puriﬁed
from prostate tumors based on coexpression of the human
pluripotent stem cell marker TRA-1-60 with CD151 and
CD166. Such triple-marker-positive TICs possess stem cell
characteristics and multipotency as demonstrated by in vitro
sphere formation and in vivo tumor initiation, respectively.
2.2.6. Pancreas. Pancreatic adenocarcinoma continues to be
one of the deadliest cancer-related diseases in the world [30].
Little progress has been made since the past introduction
of the chemotherapeutic agent gemcitabine, which remains
the ﬁrst-line chemotherapeutic agent in pancreatic cancer.
The prognosis of patients diagnosed with pancreatic cancer
remains extremely poor [31]. Emerging evidence suggests
that the majority of pancreas tumors display vital functional
heterogeneity in their respective cell populations. However,
a small subpopulation of tumor cells that have acquired
the same somatic mutations as the other tumor cells with
epigenetically distinct is responsible for tumor initiation,
growth, and metastasis [32, 33].
Researchers identiﬁed a highly tumorigenic subpopu-
lation of pancreatic cancer cells expressing the cell sur-
face markers CD44, CD24, and epithelial-speciﬁc antigen
(ESA) using a xenograft model of immunocompromised
mice for primary human pancreatic adenocarcinomas [34].
Pancreatic cancer cells expressing the cell surface markers
CD44, CD24, and ESA had at least a 100-fold increased
tumorigenic potential compared with nontumorigenic cells.
The CD44+CD24+ESA+ pancreatic cancer cells showed the
stem cell properties of self-renewal, the ability to produce
diﬀerentiated progeny, and increased expression of the
developmental signaling molecule sonic hedgehog (SHH).
More recent data suggested an abundant expression of
ALDH-1 in normal pancreas tissue [35]. It was found that
a subset of adult centroacinar cells and terminal ductal
epithelial (CA/TD) cells were characterized by high levelsJournal of Biomedicine and Biotechnology 5
Table 1: Comparison of the biomarkers of CSC and normal stem cell.
Cancer type CSC marker Normal stem cell Marker References
Acute myelogenous leukemia CD34+CD38− Mouse embryonic stem cell Oct-4 [64]
SSEA-1 [65]
Glioma Nestin, HOXD9 Human embryonic stem cell SSEA-3
SSEA-4, Oct-4 [65]
Breast ALDH1, TAZ
CD44+/CD24−/lin−
TRA-1-60
TRA-1-81 [65]
Colon CD166 Neural stem cell CD133 [66]
Prostate TRA-1-60
CD151, CD 166 Nestin [66]
Pancreas ESA Hepatic stem cell EpCAM [43]
Liver CD90, EpCAM
CD13 Mammary stem cell CD49f+EpCAM
neg-low [67]
Breast, liver, and pancreas ALDH ALDH1 [17, 68]
Glioma, lung, colon, pancreas, and
liver CD133
Pancreas, colon, and liver CD24, CD44
Breast, pancreas, and lung ABCG2
CD49f: α6 integrin; Lin: Lineage surface antigen; SSEA: stage-speciﬁc embryonic antigen.
of ALDH1 enzymatic activity. CA/TD cells carry signiﬁcant
progenitorcapacitiesandmaycontributetothemaintenance
of tissue homeostasis in adult mouse pancreas. Subsequently,
Kim et al. sought to determine the relationship of ALDH
and CD133 whose marker best enriches for pancreatic
TICs and the suﬃciency of ALDHhi and ALDHlo cell
populations for tumor-initiation when enriched or depleted
of cell populations also expressing CD133 [36]. Finally,
they demonstrated that cell populations enriched for high
ALDH activity alone were more eﬃcient and fulﬁll the major
criteria of a CSC and eﬃciently recapitulate the phenotype
of the original tumor independent of CD133 cell surface
expression, using a strict, direct xenograft tumor system and
limiting dilutions of sorted human pancreatic cancer cells
injected into NOD/SCID mice [36].
It was also suggested that SP cells were enriched in CSCs
of pancreas cancer and validated an intriguing regulatory
mechanism of the cancer stem cell-related phenotypes,
which could represent a novel therapeutic target [4, 37].
2.2.7. Liver. Hepatocellular carcinoma (HCC) accounts for
over 90% of primary liver cancer in adults. The ﬁrst-
line treatment for HCC is liver transplantation or surgical
resection [37, 38]. However, most HCCs are inoperable
because patients present at advanced stages. Even after
surgical resection, the long-term prognosis of HCC remains
unsatisfactory due to high recurrence rates. Recently, there
has been mounting evidence in support of the existence of
CSCs in hepatocellular carcinoma. CD24 was found to be a
functional liver tumor-initiating cell (T-IC) marker. CD24+
HCC cells were found to be critical for the maintenance,
self-renewal, diﬀerentiation, and metastasis of tumors and to
signiﬁcantly impact patients’ clinical outcome [39]. In liver,
CSCs can also be identiﬁed by several other cell markers,
including CD44, CD133, CD90, CD13, EpCAM, OV6, and
ALDH enzymatic activity, or by selecting for SP cells which
express an adenosine triphosphate-binding cassette (ABC)
membrane transporter, such as MDR1 and ABCG2 [40].
However, generally accepted markers of CSCs in HCC have
not been identiﬁed.
In summary, recent studies indicate that the expression
of the surface markers is not suitable as a universal signature
to detect CSCs in cells derived from diﬀerent tumor types.
It is likely that a panel of markers will be required to assess
the presence of reliable and true CSCs in tumors. Although
thelistofCSCmarkersisnotyetﬁnished,amethodtoisolate
and substantially enrich CSCs for cancer research is provided
(Table 1).
3.ImagingofCancer Stem-Like
(or Cancer)Cells
Noninvasive molecular imaging technology is an eﬀective
and novel approach to visualize living cells in vivo. It also
plays a critical role in tracking the location and activity
of CSCs [41]. Now that CSCs are being identiﬁed and
characterized in diﬀerent tumor types, they are postulated
to be responsible for tumor development, metastasis, and
relapse after conventional therapies. To date, limited studies
were investigated on the detection of various types of CSCs
by molecular imaging methods (Table 2).
Examples will be given for the identiﬁed biomarkers of
the tumor stem-like (or tumor) cells with molecular imaging
techniques. Speciﬁcally, the feasibility of molecular imaging
of prostate stem cell antigen-(PSCA-) positive prostate
cancer was evaluated using an intermediate size antibody
fragment by micropositron emission tomography (micro-
PET) imaging [42], cell tracking with magnetic resonance
imaging (MRI) after the hepatic progenitor cells labeled
with EpCAM microbeads [43], CD133-speciﬁc monoclonal6 Journal of Biomedicine and Biotechnology
Table 2: Molecular imaging in tracking tumor stem-like cells.
Imaging agent Molecular
imaging Biomarker Model
64Cu-ATSM PET CD 133 Colon cancer
Antibody magnetic microbead MRI ESA Liver cancer
HA-MNCs MRI CD44 Breast cancer
Antibody AC133.1 FMT CD133 CD133-overexpressing glioblastoma
Optical bifusion reporter genes BLI CD44 Breast cancer
GSC-targeting peptide BLI Nestin Glioma
199b Luc-1 BLI CD133 Medulloblastoma tumor
Adv5-199b PET/CT
antibody AC133.1 used for quantitative ﬂuorescence-based
optical imaging of mouse xenograft models [44], and so on.
3.1. Positron Emission Tomography (PET). PET imaging is a
highly sensitive system that has advantages over traditional
methods, as it permits noninvasive, real-time tracking in
vivo. To our knowledge, few published studies were found
to track the CICs in cancers with PET imaging. We will
give an example of a generated stem cell surface marker
speciﬁc probe to prostate cancer by micro-PET imaging.
In the human prostate cancer LAPC-4 xenograft model, a
number of candidate molecules were identiﬁed with high
expression using representational diﬀerence analysis (RDA),
a PCR-based subtractive hybridization strategy [45, 46]. One
promising candidate, PSCA, is a prostate-speciﬁc cell surface
antigen expressed strongly in both androgen-dependent and
-independent LAPC-4 tumors. Elevated levels of PSCA were
correlated with increased tumor stage, grade, and androgen
independence [47]. PSCA located at chromosome 8, band
q24.2, is a prostate-speciﬁc gene, encoding a 123-aa protein
withanamino-terminalsignalsequence,acarboxyl-terminal
GPI-anchoring sequence, and multiple N-glycosylation sites
[46]. Researchers had isolated and characterized a series of
monoclonal antibodies directly against PSCA. The localiza-
tion of PSCA had been detected using these antibodies.
Leyton et al. revealed a humanized radioiodinated mini-
body as a PET imaging agent for the detection of PSCA-
expressing tumors [42]. Visualization of PSCA-positive
prostatecancerisfeasibleusinganintermediatesizeantibody
fragment at 21 hours. The genetically engineered radioio-
dinated (124Io r131I) 2B3 minibody as a novel antibody
fragment for speciﬁc targeting and potential PET imaging
agent for PSCA-expressing prostate cancers was introduced
[48]. Then an aﬃnity-matured minibody that ranked second
in aﬃnity for PET imaging of PSCA-expressing tumors was
selected as the best tracer [49]. Currently, this candidate
is under development for evaluation in a pilot clinical
imaging study. Interestingly, two antibodies, anticlaudin 4
and anti-PSCA, were radio-labeled with iodine 125 (125I)
for imaging pancreatic cancer xenografts in mice using
gamma scintigraphy and single-photon emission computed
tomography-computed tomography (SPECT/CT). It has
been demonstrated that they are promising as radiodi-
agnostic and possibly radiotherapeutic agents for human
pancreatic cancers [50]. Antibodies or their constituent parts
can be conjugated with radionuclides to carry them into
tumors speciﬁcally and eﬀectively. Similar to the speciﬁc
normal stem cell biomarker detected in prostate cancer,
which was used as early diagnosis marker in prostate cancer,
tracking the CSCs biomarkers by PET imaging is also
promising.
64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-
ATSM), a PET imaging agent, accumulated in regions of
CD133+ high expression, which are then killed by radiation,
resulting in a decrease of the percentage of CD133+ cells
[51]. In vivo (colon 26-bearing mice) studies showed that
64Cu-ATSM treatment inhibited tumor growth. The per-
centage of CD133+ cells and metastatic ability in 64Cu-
ATSM-treated tumors was decreased compared with that in
control animals. 64Cu-ATSM could be a potential internal
radiotherapy agent aﬀecting the tumor’s hypoxic regions
with a high density of CD133+ cells, designated as CSCs.
Therefore, tracking CSCs biomarkers and evaluating therapy
eﬃciency are feasible and attractive. Further studies with
more kinds of CSCs biomarkers would be needed to clarify
the precise applications.
3.2. Magnetic Resonance Imaging (MRI). Magnetic reso-
nance imaging is a noninvasive modality and can provide
information on the anatomy, function, and metabolism
of tissues in living subjects with no ionizing radiation.
This imaging technique is increasingly performed in clinical
diagnostics. Epithelial cell adhesion molecule (EpCAM) also
known as epithelial-speciﬁc antigen (ESA) or CD326, a cell
surfaceantigen,isfoundonliverCSCs,onhepaticprogenitor
cells including human hepatic stem cells (hHpSCs) and
hepatoblasts (hHBs), and on proliferating epithelial cells in
other tissues. McClelland et al. have evaluated the feasibility
of cell tracking with MRI after the hepatic progenitor cells
labeled with EpCAM microbeads before or after transplan-
tation. Then the transplanted hHpSCs could be monitored
and counted repeatedly in the same host by injection of
the labeled MRI probe [43]. Additionally, magnetic iron
microbeads coupled with HEA-125 monoclonal antibody
against the epithelial cell adhesion molecule, abbreviated
as EpCAM microbeads, have been developed primarily for
the positive selection or depletion of EpCAM-positive cells.
The magnetic labeling methodology is applicable to otherJournal of Biomedicine and Biotechnology 7
surface antigens for which antibody magnetic microbeads
are available [43]. Antibodies or their constituent parts can
be conjugated with nanoparticles or other substances, to
carry them more speciﬁcally and eﬀectively into tumors. The
biological eﬀects of monoclonal antibodies are supposed to
be possible if targeting antigens are present in cancer stem-
like cells [52].
CD44 is a cell surface glycoprotein overexpressing in
breast CSCs and plays an important role in promoting
cancer cell proliferation, invasion, and tumor-associated
angiogenesis [53]. First, researchers synthesized pyrenyl HA
(Py-HA) conjugates as CD44-targetable surfactants capa-
ble of simultaneously encapsulating magnetic nanocrystals
and targeting CD44 using HA and 1-pyrenebutyric acid
(Py). Finally, Py-HA conjugates and magnetic nanocrystals
were used to formulate HA-MNCs. Their study suggested
that HA-MNCs can be a potent cancer-speciﬁc molecular
imagingagentforeﬀectivediagnosisofCD44-overexpressing
breast cancer via MR imaging [53]. Furthermore, CG-
rich duplex containing prostate-speciﬁc membrane antigen
(PSMA) aptamer-conjugated thermally cross-linked super
paramagnetic iron oxide nanoparticles (TCL-SPIONs) was
reported as prostate cancer-speciﬁc nanotheranostic agents
[54]. These agents were capable of prostate tumor detection
in vivo by MRI and selective delivery of drugs to the tumor
tissue, simultaneously.
3.3. Optical Imaging. CD133/prominin (AC133) has been
identiﬁed as a CSC marker in a variety of tumors. Tsurumi
et al. showed that CD133-speciﬁc monoclonal antibody
AC133.1wasusedforquantitativeﬂuorescence-basedoptical
imaging of mouse xenograft models [44]. Near-infrared ﬂu-
orescence molecular tomography (FMT), a highly sensitive
and fully quantitative technology, was applied as the in
vivo imaging modality. Imaging worked well using CD133
overexpressing cell line however, the implanted xenograft
HCT116 cells, which express CD133 at an endogenous level,
had limitations. The lower CD133 expression level of the
HCT116 wild-type tumors led to a generally lower signal
to noise ratio compared to CD133-overexpressing tumors.
They provided the ﬁrst evidence that noninvasive antibody-
based in vivo imaging of tumor-associated CD133 is feasible
and that CD133 antibody-based tumor targeting is eﬃcient.
In breast cancer, it was demonstrated that with noninva-
sive imaging approaches, as few as 10 CD44+ cells of stably
labeled breast cancer stem cells (BCSCs) could be tracked
in vivo by bioluminescence imaging (BLI) [41]. Imaging
revealed that CD44+ cells from both primary tumors and
lung metastases were highly enriched for tumor-initiating
cells. The BCSCs were tagged through expression of optical
bifusion reporter genes to facilitate their visualization in the
living human-in-mouse breast cancer xenograft model in
NOD/SCID mice. Such reporters included ﬁreﬂy luciferase
(Luc)forwhole-bodytrackingofcellsviaBLIandﬂuorescent
proteins. In order to label BCSCs, dual-function BLI-
ﬂuorescent reporter constructs constituting the Luc coding
sequence (Luc2) fused to that of ﬂuorescent proteins were
used. They fused Luc2 to enhanced GFP (eGFP) or the
red ﬂuorescent protein td-Tomato (Tom), which improved
detection in vivo relative to GFP. They established optimized
parameters to transduce primary or passaged BCSCs with
lentiviral vectors encoding Luc2-eGFP (L2G) or Luc2-Tom
(L2T) fusion genes; thereby one cell in vitro and minimum
of10cellsoflabeledBCSCscouldbenoninvasivelyvisualized
at 16 hours after implantation, thus greatly enhancing the
accuracy and eﬃciency of tumorigenic assays compared with
traditional monitoring assay. This study implied that the
optimized strategy for labeling BCSCs with optical reporter
genes can be applied to studies with CSCs in other tumors
such as colon cancer, brain tumor, head-and-neck cancer,
and leukemia, and to evaluate other putative CSC markers
(e.g., CD24, CD133, EpCAM, ALDH1, etc.).
In addition, Vlashi et al. demonstrated that reduced
26S proteasome activity is a general feature of CICs for
human glioma and breast cancer cells that can easily be
exploited to identify, track, and target them in vitro and in
vivo [55]. A ﬂuorescent protein (ZsGreen) is a target of the
26S proteasome. The ﬂuorescent positive cells had increased
sphere-forming capacity, expressed CSC markers, and lacked
diﬀerentiation markers in vitro. When injected into nude
mice, ZsGreen-positive cells were approximately 100-fold
more tumorigenic than the opposite cells. It was required
approximately 100 ZsGreen-positive cells to form tumors in
vivo. They proposed that ZsGreen-positive cells need to be
furtherpuriﬁedtoobtainapureCSCpopulation.Trackingof
CICsbyﬂuorescenceimaginginvivomayfacilitatethesearch
for novel therapeutic approaches that improve radiation
therapy outcome.
Nestin, one of the most reliable stemness markers, is
used to evaluate the identity of normal neural stem cells and
glioma stem cells (GSCs). Samuel Beck et al. isolated a GSC-
targeting (GSCT) peptide that demonstrated selective bind-
ingisotypesofNestinproteinsspeciﬁcallyexpressedinGSCs.
In human glioblastoma tissue specimens, the ﬂuorescence-
conjugated GSCT peptide could visualize putative GSC
populations, showing its possible use as a diagnostic agent
(Figure 2). Intravenously injected GSCT peptide eﬀectively
penetrated into tissues, speciﬁcally accumulated in gliomas
that arise from implantation, and predominantly targeted
Nestin-positive cells in these tumors (Figure 3)[ 27].
3.4. Multimodal Imaging. Molecular imaging of cancers has
been characterized based on the sensitivity and selectivity
of a single cancer probe targeting a cancer biomarker
of a speciﬁc cancer cell line. The goal of multimodality
imaging is to combine the best features of separate modal-
ities. Researchers had designed a multimodal nanoparticle-
based simultaneously multiple aptamers and RGD targeting
(SMART)cancerprobetargetingmultiplecancerbiomarkers
to enhance the speciﬁcity and signal sensitivity for various
cancers. The SMART probe was conjugated to a multimodal
nanoparticle that is capable of concurrent ﬂuorescence,
MRI, and radionuclide imaging. Unlike a single aptamer
or peptide-conjugated multimodal cancer probe targeting
a single cancer biomarker, the multimodal SMART cancer
probe simultaneously targets multiple cancer biomarkers in
various cancer cells, resulting in enhanced targeting eﬃcacy
and signals [56].8 Journal of Biomedicine and Biotechnology
Figure 2: GSCT selectively binds Nestin-positive tumor cells in human GBM tissues. Paraﬃn-embedded human GBM tissue sections were
stained with a biotinylated-GSCT (B-GSCT) peptide (Green) and Nestin antibody (Red). This immunoﬂuorescence analysis revealed that
most B-GSCT peptide-targeting tumor cells are colocalized with Nestin-positive tumor cells [27]. With reprint permission from Elsevier.
Garzia et al. demonstrated that miR-199b-5p over-
expression blocks expression of several CSC genes and
impairs the engrafting potential of medulloblastoma tumor
(MB) stem-cell-like (CD133+) subpopulation of cells in the
cerebellum of nude mice. They used PET-CT fusion imaging
to investigate the relationship between miRNAs targeting the
MB tumors. The expression of miR199b-5p can deplete this
tumor cell compartment, indicating the use of miRNA as an
interesting therapeutic approach for the targeting of CSCs in
brain tumors [57].
An important recent development is the concept of
multimodality fusion reporter systems. Researchers have
described fusion modality reporter genes for whole mouse
body ﬂuorescent, bioluminescent, and nuclear imaging [58].Journal of Biomedicine and Biotechnology 9
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Figure 3: Homing of GSCT peptide to GSC-derived tumors in vivo [27]. (a) In vivo biodistribution of GSCT peptide was examined by
intravenous injection of Q-dot 800-conjugated GSCT (QGSCT) or control peptide in mice bearing subcutaneous tumors derived from
the injection of Id4-driven mouse GSCs. Whole-body bioﬂuorescence images were obtained 24h after injection of Q-GSCT and Q-control
peptides. (b) In vivo biodistribution of Q-Dot 800-conjugated GSCT or control peptide in orthotopic brain tumor models. Whole-body
bioﬂuorescence images were obtained 4 days after injection of Q-GSCT and Q-control peptides in mice bearing orthotopic brain tumors
derived from the injection of Id4-driven mouse GSCs. (c) Fluorescence images of Q-GSCT peptides in tumors and organs extracted from
mice bearing subcutaneous tumors are shown in Figure 3(a). (d) Fluorescence images of Q-GSCT peptides in brains extracted from mice
bearing orthotopic tumors are shown in Figure 3(b). With reprint permission from Elsevier.
The development of multifunctional reporter platforms has
the potential to provide both diagnostic and therapeutic
capabilities in cancer treatment.
4. Discussion
Researchers have tried for decades to understand cancer
development in the context of therapeutic strategies. The
CSC model provides an attractive concept to explain why
cancer contains cells resistant to chemo- and radiotherapies
[2, 3]. A minority population of CSCs has the ability to self-
renew, whereas the majority of cancer cells have the limited
or no ability to proliferate in breast and brain tumors [59].
There has been acceptance of the idea that the remaining
tumorcellsafteranticancertherapyhaveadistinctmolecular
phenotype that confers resistance to the therapies [2, 3].
CSCs are tumorigenic and possess the metastatic phe-
notype. Interestingly, many studies show that cells of CSC
phenotypes also express stem/progenitor-associated genes
which may suggest the possible link between CSCs and
normal stem cells. A comparison of the biomarkers of CSC
and normal stem cell was shown in Table 1. CSCs share
common features with normal stem cells, most obviously the
characteristic of self-renewal. Current knowledge indicates
that a specialized microenvironment, the stem cell niche, is
one of the factors regulating normal stem cell maintenance
and self-renewal [59]. In analogy to the normal intestinal
stem cell niche, researchers conclude that there is a CSC
niche that is probably composed of a combination of
stromal cells and more diﬀerentiated progeny and delivers
crucial signals to the CSCs. Tumors may arise through
a series of mutations that disrupt normal development10 Journal of Biomedicine and Biotechnology
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Figure 4:ParadigmoftheapplicationofmolecularimaginginCSCsdetectionbasedoncancerstemcellmodel.Redandblueindicatecancer
stem cells (CSCs) and non-CSCs, respectively.
pathways, and a population of continuously self-renewing
cells must arise [59]. Genes (e.g., Bmil 1) that program
self-renewal rather than diﬀerentiation are likely to be
candidate oncogenes [60–62]. Exploring the mechanism
regulating stemness features of CSCs in the tumorigenic
process will beneﬁt developing treatment aimed at destroy-
ing CSCs without adversely aﬀecting normal stem cell
characteristics.
CSCs may often constitute only a small population of
tumor mass thus, there is a need for imaging modalities
and probes that provide high-sensitivity and high-imaging
resolution. Molecular imaging is emerging as a promising
strategy with which to shed light on the clinical application.
This technique has the potential to become a powerful
technique for monitoring the history and the fate of CSCs
and for evaluating response to therapy. The precise real-time
imaging of CSCs in tumors at molecular and cellular levels is
challenging. Single-luciferase models require animals to be
injected with the luciferin substrate, and the limitation of
the signal in xenograft model of human neoplasia requires
expression of luciferase is at least 2,500 cells for proper
detection [63]. The good option may be concurrently
employing more than one ﬂuorophore and highly sensitive
detectors. MRI detects the presence of SPIO contrast agents
regardless of whether the cells are alive or dead; it is also
challenged to count the number of SPIO labeld cells in
MRI on account of the contrast agent dilution during cell
division, transfer to other cells, and the exist of other source
of iron in tissue. To overcome limitations, the multimodality
of imaging techniques (e.g., magnetic and optical) can be
developed for applications in medicine.
For noninvasive imaging of CSCs as well as CSC-
speciﬁc therapies, the targeting of cell surface proteins using
antibodies or other receptor ligands is particularly relevant
(Figure 4). Noninvasive imaging of CSCs would be critical in
the management of malignant cancer disease, for example,
for determining prognosis of patients, using as a diagnosis
parameter, and monitoring therapeutic eﬃcacy.
5. Conclusions
There is increasing evidence to support the existence of
CSC that is identiﬁed by several markers, including CD133,
CD44, CD24, and ALDH, or by selecting for the SP cells.
Interestingly, no single marker is exclusively expressed by
CSCs. Thus, in order to identify CSCs, the various combina-
tions of diﬀerent biomarkers may be possible. Targeting and
elimination of the small population of CSCs hold attractive
cancer treatment and avoid tumor recurrence.
Tracking of CSCs in vivo may facilitate the search for
novel therapeutic approaches that improve radiation therapy
outcome. The development of therapeutic agents speciﬁ-
cally targeting CSCs together with a revised radiotherapy
or chemotherapy protocol will alter the traditional poorJournal of Biomedicine and Biotechnology 11
prognosis of tumor patients. Novel drugs that selectively
target CSCs oﬀer great promise for more completed can-
cer treatment; however, designing and ﬁnding such drugs
remain a great challenge.
S t i l l ,m u c hw o r kn e e d st ob ed o n ei no r d e rt oc o m p l e t e l y
understand the origin of CSCs, as well as the mechanisms
regulating their stemness features in the tumorigenic process
and their increased resistance to chemotherapy and radio-
therapy. Although the tracking of circulating CSCs is still
hampered by technological challenges, we expect personal-
ized diagnosis and therapy of cancers to be established based
on increased studies and applications of molecular imaging
of biomarkers in cancer stem-like cells.
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